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Summary: The relationship between vitamin C and pulmonary function has been reported to be a 
protection against pulmonary dysfunction.  Sympathomimetics like salbutamol are respiratory smooth 
muscle relaxants.  This study is aimed at investigating the roles of vitamin C and salbutamol on 
pulmonary function in a Nigerian population. Undergraduate medical students who gave their informed 
consent were clinically screened and thirty (30) selected.  The subjects were grouped, and given 
Ascorbic acid and Salbutamol.  Spirometry and peak flow measurements were done on each subject.  
Ascorbic acid was given orally at a dose of 1.50 mg /kg body weight; and salbutamol at a dose of 70 
μg/kg body weight, orally.  Measurements were taken an hour after each administration of the drugs. 
Results show mean PEFR in male and female control as 485.76 ± 51.40 L/min, and 329.87 ± 34.90 
L/min respectively.  Ascorbic acid increases PEFR much more than salbutamol VT, ERV, IC, VC and 
IRV were increased by ascorbic acid while Salbutamol decreased ERV, IC, VC and IRV.  The study 
supports the performance – enhancing role of ascorbic acid, more pronounced in the males than 
females.  There do not seem to be any beneficial roles of salbutamol in asymptomatic individuals. 
 
 





Lung volume is a determinant of the 
vascular resistance in the pulmonary bed.  The 
mechanism of breathing involves interplay of 
forces supporting and moving the lungs with 
the chest wall, in addition to overcoming 
resistance.  The elasticity of the lungs is 
conventionally believed to be dependent on the 
surfactant (West, 1990, Gala et al, 1998). 
Analysis of static pressure – volume data 
could be useful in the identification of 
pulmonary function abnormality, and in the 
probable categorization of the dominant 
mechanism for restrictive ventilatory defects 
(Aggarwal et al, 2000).  Topulos et al (2001) 
posited that pressure volume characteristics of 
the lungs microcirculation are important 
determinants of pulmonary perfusion.  It is 
however, not yet clear, whether muscle 
function can be used to predict respiratory 
changes in exercise limitations (Mayer et al, 
2000).  Exercise limitation is usually 
associated with reversible lung restriction and 
inefficient ventilation at rest and during 
exercise (Aggarwal et al, 2000). 
The β-agonists has relaxant effects on 
respiratory smooth muscles, acting through the 
calcium cyclic adenosine monophosphate 
(cAMP) mechanism.  They also have anti – 
permeability effects preventing histamine – 
induced microvascular efflux of protein and 
fluid (Anderson and Johnson, 1979).  The 
effects of ascorbic acid on pulmonary function 
have been investigated (Hu et al, 1998, Ibadin 
and Osubor, 1999).  Weber et al (1996) 
reported that ascorbic acid protects against 
pulmonary dysfunction.  Ascorbic acid is an 
antioxidant (Grievink et al, 1998).  
Sympathomimetics (e.g. Salbutamol) are being 
used in the treatment of obstructive pulmonary 
diseases following the Henry – Perrson’s 
discovery of the β - adrenoceptor selectivity 
(Lands et al, 1997). 
The support of baseline absolute lung 
volumes on clinical decision – making is 
claimed not to be necessarily great (Walamies, 
1998).  However, the implication of pulmonary 
function defects on several clinical conditions 
can only but justify the value of lung volume 
studies in clinical decision making (Igneito et 
al 1998; Yap et al, 2000: Cassino et al, 2001; 
Fuyita et al, 2001).  In our environment, 
ascorbic acid and sympathomimetics are 
frequently used clinically, and even on self 





medications.  Therefore, the study is carried 
out to compare the effects of ascorbic acid and 
salbutamol on lung function of asymptomatic 
subjects. 
 
Materials and Methods 
The study was carried out on volunteer 
undergraduate medical students who gave their 
informed consent.  The subjects were 
interviewed and physically examined.  Those 
with respiratory and or cardiovascular 
disorders were excluded.  Thirty (30) subjects 
made up of fifteen (15) males and females 
each were randomized to control, ascorbic 
acid, and salbutamol groups. 
Each subject had peak flow measurements 
and spirometry done.  The Spirometer was 
filled with water to level mark, and the 
recorder adjusted to 4.5L mark.  The age, 
weight and height of the subjects were taken.  
Each subject was comfortably seated, and 
connected to the apparatus.  Recordings were 
taken at a drum speed of 2.5 mm/sec. 
 
Drug Administration: 
The ascorbic acid was given orally at a 
dose of 1.5 mg/kg body weight, and 
salbutamol at a dose of 70 μg/kg body weight, 
also orally.  Measurements were taken after 
one hour of the administration of drugs. 
 
Data Analysis: 
The data was analyzed using the statistical 
package for Social Sciences,  version 8.0.  The 
student’s t-test was employed.  The level of 





The mean age of the male subjects was 
22.87 years and for the female, 22.01 years.  
The mean weights were 63.46 kg and 61.09 kg 
male and female respectively.  The mean 
heights were 1.71 m for males and 1.68 m for 
females.  These are shown in Table I. 
 
Peak flow measurements: 
The peak flow rate in the control groups 
for males and females were 485.78 ±  51.45 
L/min and 329.87 ± 34.90 L/min respectively.  
The PEFR in the male was significantly higher 
than in the female control group (P<0.05).  The 
PEFR for the ascorbic acid groups were 571.00 
± 37.16 L/min and 333.00 ± 36.42 L/min for 
males and females respectively.  The male 
ascorbic acid group was significantly higher 
than the control group (P<0.05) and the female 
group (P<0.05).  The PEFR in the salbutamol 
groups were 513.26 ± 31.96 L/min in the male 
and 389.66 ± 16.05 L/min in the female groups 
respectively.  PEFR was raised in the 
salbutamol groups, but not significantly higher 
than the controls (P<0.05).   The male 
salbutamol group differs significantly from the 
female group (Table 2). 
The results for the spirometry are shown 
in Table 3.  Tidal Volume (VT ) in the control 
groups are 0.60 ± 0.11L and 0.55 ± 0.11 L in 
the males and the females respectively.  The 
expiratory reserve volume (ERV) was 
significantly higher (P<0.05) in the male 
ascorbic acid group, and lower (P<0.05) in the 
male salbutamol group.  There are no 
significant changes in the female group.  The 
inspiratory capacity (IC) was not significantly 
different in the male group on ascorbic acid 
(P<0.05), but Salbutamol significantly lowers 
IC in the females (P<0.05).  Vital capacity 
(VC) is significantly (P<0.05) raised in the 
male by ascorbic acid, and in the female by 
salbutamol.  The inspiratory reserve volume 
(IRV) did not show any significant difference 
from the control for any of the test groups. 
 
Table I: Some Anthropometric data of subjects 










Male 22.87 1.71 63.46 
Female 22.01 1.68 61.09 
  
Table 2:  Mean Peak Expiratory Flow Rate 
following the administration of 
Ascorbic acid and Salbutamol 
(L/min) 
 
 Male Female 
Control 485.76 ± 
51.45 L/min 






333.00 ± 36.42 
L/min 
Salbutamol  513.26 ± 
31.96 L/min 












Table 3: Mean Lung Volumes and capacities following the administration of ascorbic acid and 
salbutamol (L) 
 
             Control Ascorbic Acid Salbutamol 
 Male Female Male Female Male Female 




0.76 ± 0.12 0.65 ± 0.12 0.79 ± 0.15 0.63 ± 0.12 




1.72 ± 0.23 1.02 ± 0.11 0.82 ± 0.17 0.92 ± 0.14 




3.93 ± 0.24 3.39 ± 0.10 2.63 ± 0.16 2.39 ± 0.21 




5.59 ± 0.33 4.91 ± 0.05 3.56 ± 0.02 3.45 ± 0.30 




2.97 ± 0.12 2.73 ± 0.13 2.13 ± 0.10 2.01 ± 0.25 
 
Key  
VT - Tidal Volume 
ERV - Expiratory Reserve Volume 
IC - Inspiratory Capacity 
VC - Vital Capacity 
IRV - Inspiratory Reserve Volume 
 
Discussion 
The standard value for peak expiratory 
flow rate (PEFR) is between 510 and 560 
L/min (Slonim and Hamilton, 1987). In our 
study, the PEFR value of 485 L/min is lower 
than this range.  Ascorbic acid (Vitamin C) 
improved the PEFR to 571 L/min.  This study 
does not corroborate the study of Ibadin and 
Osubor (1999) which reported a lack of effect 
of vitamin C on pulmonary function.  Vitamin 
C protected against loss of pulmonary function 
(Hu et al, 1998) Grievmik et al, (1998) also 
supported the beneficial role of vitamin C in 
respiratory dysfunction. 
In the present study, the male PEFR 
values are expectedly higher than female 
values (485 L/min and 329 L/min 
respectively).  The vitamin C effect shows a 
significant (P<0.05) increase in PEFR, 
indicating a minimal response of smooth 
muscle to sympathomimetics.  Lands et al 
(1967) posited that the β- adrenoceptor 
agonists actually become important in 
obstructive pulmonary disorders.  The report of 
Perrson (1979) that the effect of β- agonist is 
more pronounced in healthy lungs compared to 
diseased lungs, is not corroborated by the 
present study. 
The tidal volume in the control group 
(0.6L and 0.55 L for males and females 
respectively) corroborated the standard values 
of 0.5L to 0.6L.  Ascorbic acid and salbutamol 
did not significantly increase the VT  in both 
sexes (P>0.05).  Expiratory reserve volume 
(ERV) in our study population was lower for 
all groups than the standard values of 1.0L to 
1.2L.  Vitamin C increased ERV in males but 
not in females, while Salbutamol decreased 
ERV in males (P< 0.05) but not in females (P 
> 0.05).  ERV reflects the thoracic and 
abdominal muscles strength, thoracic mobility 
and a balance of elastic forces affecting 
spontaneous expiration (Gelb and Zamel, 
2001).  Our subjects have less reserve 
expiratory capabilities.  This might be due to 
the fact that most medical students are not 
engaged in active regular bodily exercises. 
The inspiratory reserve volume IRV in 
our study is significantly lower than the 
standard values.  Ascorbic acid increases IRV 
in both sexes while salbutamol decreases it.  
IRV describes a balance between lung and 
chest elasticity, muscle strength and thorax 
mobility. 
Vital capacity (VC) describes the 
physical unit of the rising tidal volume during 
maximal ventilatory effort.  Our study shows a 
reduced VC in controls and in the salbutamol 
group.  Ascorbic acid significantly (P < 0.05) 
increases VC.  VC is usually reduced in severe 
respiratory muscle weakness (Syabbalo, 1998). 
Discrepancies in IRV and ERV may be 
explained by a lack of parenchymal airway 
narrowing (Stanescu et al, 200).  The IC is 
more frequently used than IRV.  At low 
volumes, it is expected that the vasculature 
would strain and stiffen (Topulos et al, 2000; 
Schulz et al, 1999).  Our study shows IC rising 
with ascorbic acid and falling with salbutamol.  
The exact mechanism of action is yet to be 
elucidated.  It however corroborates the 
hypothesis that ascorbic acid protects against 




the loss of pulmonary function.  Hu et al, 
(1998) have indeed reported an inverse 
relationship between vitamin C and cough.  
The relatively lower value in females in the 
present study corroborated the report that 
progesterone reduces fatigue and lowers 
exercise tolerance (Van-Haren et al, 1998). 
The Salbutamol response in this study 
supports earlier works (Pillet et al, 1998) 
which reported that β - agonist bronchodilators 
induce hypoxic vasoconstriction with no 
significant influence on ventilation parameters.  
  
Ascorbic acid indeed has beneficial effect on 
pulmonary function. 
Our study has the limitation of sample 
size, being a preliminary study.  It is intended 
that in subsequent work, the sample size would 
be increased, and we would attempt to define 
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